Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Sexual Health Reports
Erschienen in: Current Sexual Health Reports 1/2022

18.01.2022 | Male Sexual Dysfunction and Disorders (N Thirumavalavan, Section Editor)

Testosterone Use in the Perioperative Setting

verfasst von: Bailey N Goyette, Matthew T Hudnall, Joshua A Halpern

Erschienen in: Current Sexual Health Reports | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The number of men on testosterone replacement therapy (TRT) has increased dramatically in recent years. Given the potential cardiovascular risks of TRT, there has been some concern that TRT use in the perioperative setting may potentiate the inherent cardiovascular risks of anesthesia and surgical intervention. Conversely, a large proportion of men with low testosterone remain undiagnosed or untreated

Recent Findings

There are numerous benefits to TRT use in the appropriate candidate, many of which may be uniquely advantageous in the perioperative setting. Here we review of the most recent literature to examine the risks and benefits of TRT in the perioperative setting.

Summary

While studies are limited, available evidence does not suggest an increased risk of perioperative cardiovascular complications among patients using TRT, and there are small, single-center studies indicating a beneficial role for TRT use in specific surgical contexts. Further studies are needed to better delineate the unique risks and benefits of TRT in the perioperative setting.
Literatur
1.
Malik RD, Wang CE, Lapin B, Lakeman JC, Helfand BT. Characteristics of men undergoing testosterone replacement therapy and adherence to follow-up recommendations in metropolitan multicenter health care system. Urology. 2015;85:1382–8.PubMed
2.
Malik RD, Lapin B, Wang CE, Lakeman JC, Helfand BT. Are we testing appropriately for low testosterone?: characterization of tested men and compliance with current guidelines. J Sex Med. 2015;12:66–75.PubMed
3.
Baillargeon J, Urban RJ, Kuo Y-F, Holmes HM, Raji MA, Morgentaler A, Howrey BT, Lin Y-L, Ottenbacher KJ (2015) Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010. Public Health Rep Wash DC 1974 130:143–152
4.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32.PubMed
5.
6.
Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med. 1990;323:1781–8.PubMed
7.
Mangano DT, Browner WS, Hollenberg M, Li J, Tateo IM. Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA. 1992;268:233–9.PubMed
8.
Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MDL, Adams JE, Oldham JA, Wu FCW. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95:639–50.PubMed
9.
Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374:611–24.PubMedPubMedCentral
10.
• Wright TJ, Dillon EL, Durham WJ, et al (2018) A randomized trial of adjunct testosterone for cancerrelated muscle loss in men and women. J Cachexia Sarcopenia Muscle 9:482–496 . This study is a randomized controlled trial that demonstrated that adjunct testosterone improved lean body mass in patients with advanced cancer.PubMedPubMedCentral
11.
12.
Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661–7.PubMed
13.
Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, McGee D. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58:1134–43.PubMedPubMedCentral
14.
Strollo F, Strollo G, Morè M, Magni P, Macchi C, Masini MA, Carucci I, Celotti F, Ruscica M, Gentile S. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male Off J Int Soc Study Aging Male. 2013;16:33–7.
15.
Theou O, Chapman I, Wijeyaratne L, Piantadosi C, Lange K, Naganathan V, Hunter P, Cameron ID, Rockwood K, Visvanathan R. Can an intervention with testosterone and nutritional supplement improve the frailty level of under-nourished older people? J Frailty Aging. 2016;5:247–52.PubMed
16.
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer‐specific and all‐cause mortality - Psutka - 2014 - Cancer - Wiley Online Library. https://​acsjournals.​onlinelibrary.​wiley.​com/​doi/​full/​https://​doi.​org/​10.​1002/​cncr.​28798. Accessed 17 Jul 2020
17.
Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.PubMed
18.
Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN (2014) Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS One 9:e85805
19.
Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.PubMedPubMedCentral
20.
Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–8.PubMed
21.
Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–33.PubMed
22.
Baillargeon J, Urban RJ, Kuo Y-F, Ottenbacher KJ, Raji MA, Du F, Lin Y-L, Goodwin JS. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48:1138–44.PubMedPubMedCentral
23.
Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–75.PubMed
24.
Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, Maggi M. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–51.PubMed
25.
Basaria S, Harman SM, Travison TG, et al. Effects of Testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314:570–81.PubMed
26.
Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–22.PubMedPubMedCentral
27.
Layton JB, Meier CR, Sharpless JL, Stürmer T, Jick SS, Brookhart MA. Comparative safety of testosterone dosage forms. JAMA Intern Med. 2015;175:1187–96.PubMedPubMedCentral
28.
AbbVie (2021) Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men (TRAVERSE) study. clinicaltrials.gov
29.
Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. N Engl J Med. 1995;333:1750–6.PubMed
30.
Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005;353:349–61.PubMed
31.
•• Argalious MY, You J, Mao G, Ramos D, Khanna S, Maheshwari K, Trombetta C (2017) Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing noncardiac surgery. Anesthesiology 127:457–465. This study presents the most recent data on major adverse cardiac events in men on testosterone replacement therapy undergoing noncardiac surgery.PubMed
32.
•• Argalious MY, Steib J, Daskalakis N, Mao G, Li M, Armanyous S, Roselli E (2020) Association of testosterone replacement therapy and the incidence of a composite of postoperative in-hospital mortality and cardiovascular events in men undergoing cardiac surgery. Anesth Analg 130:890–898. This study presents the most recent data on major adverse cardiac events in men on testosterone replacement therapy undergoing cardiac surgery.PubMed
33.
Chong E, Ho E, Baldevarona-Llego J, Chan M, Wu L, Tay L, Ding YY, Lim WS. Frailty in hospitalized older adults: comparing different frailty measures in predicting short- and long-term patient outcomes. J Am Med Dir Assoc. 2018;19:450-457.e3.PubMed
34.
Orkaby AR, Nussbaum L, Ho Y-L, et al. The burden of frailty among U.S. veterans and its association with mortality, 2002–2012. J Gerontol A Biol Sci Med Sci. 2019;74:1257–64.PubMed
35.
George EL, Hall DE, Youk A, et al (2021) Association between patient frailty and postoperative mortality across multiple noncardiac surgical specialties. JAMA Surg 156:e205152
36.
Tatar C, Benlice C, Delaney CP, Holubar SD, Liska D, Steele SR, Gorgun E. Modified frailty index predicts high-risk patients for readmission after colorectal surgery for cancer. Am J Surg. 2020;220:187–90.PubMed
37.
Velanovich V, Antoine H, Swartz A, Peters D, Rubinfeld I. Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res. 2013;183:104–10.PubMed
38.
39.
Shahrokni A, Tin A, Alexander K, Sarraf S, Afonso A, Filippova O, Harris J, Downey RJ, Vickers AJ, Korc-Grodzicki B (2019) Development and evaluation of a new frailty index for older surgical patients with cancer. JAMA Netw Open 2:e193545
40.
Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SAP, Yeap BB. Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab. 2010;95:3165–72.PubMed
41.
Wu I-C, Lin X-Z, Liu P-F, Tsai W-L, Shiesh S-C. Low serum testosterone and frailty in older men and women. Maturitas. 2010;67:348–52.PubMed
42.
Tajar A, O’Connell MDL, Mitnitski AB, et al. Frailty in relation to variations in hormone levels of the hypothalamic-pituitary-testicular axis in older men: results from the European male aging study. J Am Geriatr Soc. 2011;59:814–21.PubMed
43.
Travison TG, Nguyen A-H, Naganathan V, Stanaway FF, Blyth FM, Cumming RG, Le Couteur DG, Sambrook PN, Handelsman DJ. Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab. 2011;96:2464–74.PubMed
44.
Aguirre LE, Jan IZ, Fowler K, Waters DL, Villareal DT, Armamento-Villareal R (2014) Testosterone and adipokines are determinants of physical performance, strength, and aerobic fitness in frail, obese, older adults. Int J Endocrinol 2014:507395
45.
Chiang JM, Kaysen GA, Segal M, Chertow GM, Delgado C, Johansen KL. Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2019;34:802–10.
46.
Wischmeyer PE, Suman OE, Kozar R, Wolf SE, Molinger J, Pastva AM. Role of anabolic testosterone agents and structured exercise to promote recovery in ICU survivors. Curr Opin Crit Care. 2020;26:508–15.PubMedPubMedCentral
47.
Smelser WW, Randall JH, Caldwell J, Glavin K, Lee EK, Nangia A, Holzbeierlein JM. Characterization of perioperative androgen profiles in men with bladder cancer undergoing radical cystectomy. Urol Oncol. 2021;39:435.e23-435.e31.
48.
Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60:1451–7.PubMed
49.
Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93:914–9.PubMed
50.
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–44.PubMed
51.
Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern Med. 2017;177:480–90.PubMedPubMedCentral
52.
Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146–55.PubMed
53.
Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2012;27:4030–41.
54.
Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2012;27:709–15.
55.
Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, Burke JF. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis Off J Natl Kidney Found. 1997;30:495–500.
56.
Lee MS, Ahn SH, Song JH. Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin. Korean J Intern Med. 2002;17:167–73.PubMedPubMedCentral
57.
Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis Off J Natl Kidney Found. 1991;17:29–33.
58.
Sheashaa H, Abdel-Razek W, El-Husseini A, Selim A, Hassan N, Abbas T, El-Askalani H, Sobh M. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron Clin Pract. 2005;99:c102-106.PubMed
59.
Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol. 2002;58:38–46.PubMed
60.
Wu W-C, Schifftner TL, Henderson WG, Eaton CB, Poses RM, Uttley G, Sharma SC, Vezeridis M, Khuri SF, Friedmann PD. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA. 2007;297:2481–8.PubMed
61.
Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670–7.PubMed
62.
Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177:471–9.PubMedPubMedCentral
63.
Aminorroaya A, Kelleher S, Conway AJ, Ly LP, Handelsman DJ. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol. 2005;152:881–6.PubMed
64.
Ardeljan AD, Meneses ZA, Neal BV, Vakharia RM, Roche MW. Increased medical complications, revisions, in-hospital lengths of stay, and cost in patients with hypogonadism undergoing primary total knee arthroplasty. J Arthroplasty. 2020;35:95–9.PubMed
65.
Moon Y-W, Kim H-J, Ahn H-S, Lee D-H (2016) Serial changes of quadriceps and hamstring muscle strength following total knee arthroplasty: a meta-analysis. PloS One 11:e0148193
66.
Holm B, Thorborg K, Husted H, Kehlet H, Bandholm T (2013) Surgery-induced changes and early recovery of hip-muscle strength, leg-press power, and functional performance after fast-track total hip arthroplasty: a prospective cohort study. PloS One 8:e62109
67.
Meier W, Mizner RL, Marcus RL, Dibble LE, Peters C, Lastayo PC. Total knee arthroplasty: muscle impairments, functional limitations, and recommended rehabilitation approaches. J Orthop Sports Phys Ther. 2008;38:246–56.PubMed
68.
Phillips SM. Current concepts and unresolved questions in dietary protein requirements and supplements in adults. Front Nutr. 2017;4:13.PubMedPubMedCentral
69.
Ji H-M, Han J, Jin DS, Suh H, Chung Y-S, Won Y-Y. Sarcopenia and sarcopenic obesity in patients undergoing orthopedic surgery. Clin Orthop Surg. 2016;8:194–202.PubMedPubMedCentral
70.
Wu B, Lorezanza D, Badash I, Berger M, Lane C, Sum JC, Hatch GF, Schroeder ET. Perioperative testosterone supplementation increases lean mass in healthy men undergoing anterior cruciate ligament reconstruction: a randomized controlled trial. Orthop J Sports Med. 2017;5:2325967117722794.PubMedPubMedCentral
71.
Amory JK, Chansky HA, Chansky KL, Camuso MR, Hoey CT, Anawalt BD, Matsumoto AM, Bremner WJ. Preoperative supraphysiological testosterone in older men undergoing knee replacement surgery. J Am Geriatr Soc. 2002;50:1698–701.PubMed
72.
Carbone S, Candela V, Gumina S. High rate of return to CrossFit training after arthroscopic management of rotator cuff tear. Orthop J Sports Med. 2020;8:2325967120911039.PubMedPubMedCentral
73.
Matsen FA, Whitson A, Neradilek MB, Pottinger PS, Bertelsen A, Hsu JE. Factors predictive of Cutibacterium periprosthetic shoulder infections: a retrospective study of 342 prosthetic revisions. J Shoulder Elbow Surg. 2020;29:1177–87.PubMed
74.
Santucci RA, Joyce GF, Wise M. Male urethral stricture disease. J Urol. 2007;177:1667–74.PubMed
75.
• Spencer J, Mahon J, Daugherty M, Chang-Kit L, Blakely S, McCullough A, Byler T, Nikolavsky D (2018) Hypoandrogenism is prevalent in males with urethral stricture disease and is associated with longer strictures. Urology 114:218–223. This study showed that low testosterone is associated with increased disease severity in men with urethral strictures.PubMed
76.
Hofer MD, Kapur P, Cordon BH, Hamoun F, Russell D, Scott JM, Roehrborn CG, Morey AF. Low testosterone levels result in decreased periurethral vascularity via an androgen receptor-mediated process: pilot study in urethral stricture tissue. Urology. 2017;105:175–80.PubMed
77.
Hofer MD, Morey AF, Sheth K, et al. Low serum testosterone level predisposes to artificial urinary sphincter cuff erosion. Urology. 2016;97:245–9.PubMed
78.
• Wolfe AR, Ortiz NM, Baumgarten AS, VanDyke ME, West ML, Dropkin BM, Joice GA, Sanders SC, Hudak SJ, Morey AF (2021) Most men with artificial urinary sphincter cuff erosion have low serum testosterone levels. Neurourol Urodyn 40:1035–1041. This is a recent study demonstrating that low testosterone is an independent risk factor for artificial urinary sphincter cuff erosion.PubMed
79.
Meerwijk EL, Sevelius JM. Transgender population size in the united states: a meta-regression of population-based probability samples. Am J Public Health. 2017;107:e1–8.PubMedPubMedCentral
80.
Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T’Sjoen GG. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017;102:3869–903.PubMed
81.
82.
Boskey ER, Taghinia AH, Ganor O. Association of surgical risk with exogenous hormone use in transgender patients: a systematic review. JAMA Surg. 2019;154:159–69.PubMed
83.
84.
Asscheman H, Giltay EJ, Megens JAJ, de Ronde WP, van Trotsenburg MAA, Gooren LJG. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164:635–42.PubMed
85.
Fernandez JD, Tannock LR. Metabolic effects of hormone therapy in transgender patients. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2016;22:383–8.
86.
van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47:337–42.
87.
Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, T’Sjoen G. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med. 2012;9:2641–51.PubMed
88.
Asscheman H, T’Sjoen G, Lemaire A, Mas M, Meriggiola MC, Mueller A, Kuhn A, Dhejne C, Morel-Journel N, Gooren LJ. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia. 2014;46:791–5.PubMed
89.
Meriggiola MC, Jannini EA, Lenzi A, Maggi M, Manieri C. Endocrine treatment of transsexual persons: an Endocrine Society Clinical Practice Guideline: commentary from a European perspective. Eur J Endocrinol. 2010;162:831–3.PubMed
90.
Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, Kaufman JM, T’Sjoen G. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol. 2013;169:471–8.PubMed
91.
Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008;93:19–25.PubMed
Metadaten
Titel
Testosterone Use in the Perioperative Setting
verfasst von
Bailey N Goyette
Matthew T Hudnall
Joshua A Halpern
Publikationsdatum
18.01.2022
Verlag
Springer US
Erschienen in
Current Sexual Health Reports / Ausgabe 1/2022
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI
https://doi.org/10.1007/s11930-021-00322-7

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise